Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Alfred Chung, MD
- Target Recruit Count
- 46
- Registration Number
- NCT05486481
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Dexamethasone or Dexmedetomidine as Adjunct in Fascia Iliaca Block During Positioning for Sub-arachnoid Block & Post-operative Analgesia After Femur Neck Fracture Surgery: A Randomized Control Trial
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Aga Khan University Hospital, Pakistan
- Target Recruit Count
- 60
- Registration Number
- NCT05484648
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Rashmi Verma, MD
- Target Recruit Count
- 12
- Registration Number
- NCT05479578
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 54
- Registration Number
- NCT05476770
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Orange County, Orange, California, United States
🇺🇸UCSF School of Medicine, San Francisco, California, United States
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Irene Ghobrial, MD
- Target Recruit Count
- 52
- Registration Number
- NCT05469893
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Dexamethasone Intravenous Versus Intrathecal in Spinal Anesthesia
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 66
- Registration Number
- NCT05470530
- Locations
- 🇪🇬
Faculty of Medicine Ain Shams University, Cairo, Egypt
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 30
- Registration Number
- NCT05459571
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 810
- Registration Number
- NCT05455320
- Locations
- 🇺🇸
University of Kansas, Westwood, Kansas, United States
🇺🇸The Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus, Ohio, United States
🇺🇸OhioHealth, Columbus, Ohio, United States
Effect of Palonosetron, Ondansetron and Dexamethasone in the Prevention of Postoperative Nausea and Vomiting
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Selcuk University
- Target Recruit Count
- 66
- Registration Number
- NCT05439798
- Locations
- 🇹🇷
Selcuk University, Konya, Turkey
A Study of Daratumumab
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 500
- Registration Number
- NCT05438043
- Locations
- 🇺🇸
University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Barnes-jewish Hospital, Saint Louis, Missouri, United States
🇧🇪ZNA Stuivenberg, Antwerpen, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.